Secured $25 million in Equity and non-dilutive financing for the early stage biotechnology company PlantForm Corporation.

Financing secured through Family Offices, Angel investors and speciality Venture Capital Funds in North America, Europe and the Middle East. Non-dilutive funding secured through Contracts and Grants from Governments and Foundations.

Established Collaborative Research and Development Agreement with Bio-Manguinhos, Fiocruz, the Ministry of Health in Brazil, to co-develop low-cost high quality drugs including a key oncology biosimilar drug, pembrolizumab.

Established a Research Collaboration with the University of Alabama at Birmingham, USA to co-develop a protein as a Medical Counter drug for treatment of Chlorine gas exposure.

Secured contracts of over $4 million from IRAP the National Research Council of Canada’s Industrial Research Assistance Program to develop antibody drug therapies for HIV/AIDS. The product has advanced to completion of successful studies in animals.

Secured a contract of over $2 million for development of a Medical Countermeasure drug from DARPA, the USA Defense Advanced Research Projects Agency. The project was completed with the establishment of a commercial scale manufacturing process.

Awarded a grant of $2 million from United States National Institutes of Health/National Institute of Allergy and Infectious Disease (NIH/NIAID) for early stage evaluation of a vaccine to an important infectious biothreat and natural pathogen.